Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Marta Venturelli, Stefano Greco, Cinzia Baldessari, Giuseppe Pugliese, Roberta Depenni, Massimo Dominici
BACKGROUND: Melanoma is an aggressive malignancy, historically characterized with a poor prognosis and few treatment options. The advent of target therapy with BRAF and MEK inhibitors, as well as immunotherapy, changed this scenario and improved the prognosis of patients with BRAF V600E mutation. These therapies are generally well tolerated. Neurological toxicities, especially polyradiculopathy, are very rare with BRAF inhibitors and MEK inhibitors although some cases have been described in recent years, regardless of the type of target therapies combination used...
December 2023: Tumori
#22
JOURNAL ARTICLE
Zhihua Guo, Yue Cai, Weiqiang Yin, Jun Huang
INTRODUCTION: Muir-Torre syndrome, presenting with cutaneous tumors and visceral malignancies, is a variant of Lynch syndrome. The development of immune checkpoint inhibitors provided novel effective treatment options for metastatic colorectal cancer patients with microsatellite instability and deficient mismatch repair. However, the use of immune checkpoint inhibitors in neoadjuvant and adjuvant settings for patients with locally advanced colorectal cancer remains undefined because of limited follow-ups in current studies...
December 2023: Tumori
#23
JOURNAL ARTICLE
Martina Dameri, Alessandro Garlaschi, Paola Cuccarolo, Andrea Ceccardi, Mario Stabile, Irene Valente, Licia Gristina, Massimo Calabrese, Alberto Ballestrero, Alberto Tagliafico, Gabriele Zoppoli
Multiple myeloma is a hematological cancer characterized by relapse after treatment and poor prognosis. Ixazomib, a second-generation protease inhibitor, is one of the most recently available treatments for relapsed or refractory multiple myeloma, while it has also shown good potential as antitumoral agent in preclinical solid tumor models such as breast cancer cell lines. Here we report the case of a 68-year-old female with multiple myeloma and an incidental cT1b (9 mm) hormone receptor positive breast cancer lesion that showed a complete pathological response to a three-month combination therapy with Ixazomib, bendamustine and dexamethasone and no signs of disease relapse during the later follow-up...
December 2023: Tumori
#24
JOURNAL ARTICLE
Jacob Stein, Hannah E Kay, Jeremy Sites, Afsaneh Pirzadeh, Benny L Joyner, Toni Darville, Marc A Bjurlin, Tracy L Rose, Ilona Jaspers, Matthew I Milowsky
Electronic cigarette, or vaping, product use-associated lung injury (EVALI) is an increasingly recognized entity with the potential for severe pulmonary toxicity. We present the case of a young man first evaluated at a tertiary care center in the United States in 2019 with newly diagnosed testicular cancer with acute respiratory failure, which was initially attributed to possible metastatic disease but eventually determined to be related to EVALI. This case highlights the clinical features of EVALI, the potential diagnostic dilemma that can arise with EVALI when occurring in the setting of malignancy and the importance of inquiring about vaping use among patients with malignancy, especially in adolescents and young adults...
December 2023: Tumori
#25
REVIEW
Francesca De Felice, Claudia Marchetti, Maria Serpone, AnnaMaria Camarda, Barbara Vischioni, Rossana Ingargiola, Daniela Musio, Ester Orlandi
PURPOSE: To evaluate the role of upper-neck irradiation versus standard whole-neck irradiation in patients with N0-1 nasopharyngeal carcinoma. METHODS: We conducted a PRISMA guideline based systematic review and meta-analysis. Randomized clinical trials assessing upper-neck irradiation versus whole-neck irradiation with or without chemotherapy in non-metastatic N0-1 nasopharyngeal carcinoma patients were identified. The studies were searched on the PubMed, Embase and Cochrane library up to March 2022...
December 2023: Tumori
#26
JOURNAL ARTICLE
Andrea Ferrari, Matteo Silva, Alice Patriccioli, Stefano Signoroni, Maura Massimino
This short piece describes a new project developed by the adolescent patients with cancer involved in the Youth Project at the Istituto Nazionale dei Tumori in Milan, Italy. This is a scheme dedicated to young cancer patients with the dual aim of optimizing medical aspects of their care and promoting a holistic approach to their needs. " I was only sixteen " is a ballad, written in English by the patients, that became a song with the help of professional musicians (and among them international star Tony Hadley, former frontman of Spandau Ballet)...
November 30, 2023: Tumori
#27
JOURNAL ARTICLE
Giorgio Bogani, Francesco Sopracordevole, Andrea Ciavattini, Alessandro Ghelardi, Enrico Vizza, Paolo Vercellini, Jvan Casarin, Ciro Pinelli, Fabio Ghezzi, Rosa De Vincenzo, Violante Di Donato, Tullio Golia D'augè, Andrea Giannini, Flavia Sorbi, Marco Petrillo, Giampiero Capobianco, Giuseppe Vizzielli, Stefano Restaino, Stefano Cianci, Giovanni Scambia, Francesco Raspagliesi
OBJECTIVE: To date, no data supports the execution of vaccination after hysterectomy for high-grade cervical intraepithelial neoplasia (CIN2+) and early-stage cervical cancer. We aim to evaluate the potential effect of vaccination after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer. METHODS: This is a multi-center retrospective study evaluating data of women who develop lower genital tract dysplasia (including anal, vulvar and vaginal intra-epithelial neoplasia) after having hysterectomy for CIN2+ and FIGO stage IA1- IB1 cervical cancer...
November 17, 2023: Tumori
#28
JOURNAL ARTICLE
Chiara L Deantoni, Aurora Mirabile, Anna Chiara, Laura Giannini, Martina Midulla, Antonella Del Vecchio, Claudio Fiorino, Andrei Fodor, Nadia G Di Muzio, Italo Dell'Oca
AIMS: Low skeletal muscle mass index (SMI) has recently emerged as an independent prognostic factor in oncological patients and it is linked with poor survival and higher treatment toxicity. The present study aims to determine the possible impact of low SMI on survival and acute toxicity in oropharyngeal patients. METHODS: Seventy-six patients with locally advanced oropharyngeal squamous cell carcinoma (stage III-IVC) were treated in our institution with Helical TomoTherapy® (HT - Accuray, Maddison, WI, USA) between 2005 and 2021...
November 17, 2023: Tumori
#29
REVIEW
Camilla Turetta, Roberta Mazzeo, Giuseppe Capalbo, Salvatora Miano, Robert Fruscio, Violante Di Donato, Francesca Falcone, Giorgia Mangili, Sandro Pignata, Innocenza Palaia
Bartholin gland carcinoma is an extremely rare disease. Information regarding treatment is scarce and there is no strict consensus on best practice. All studies reporting cases of Bartholin's gland cancer were screened and evaluated for inclusion. Baseline characteristics of studies were extracted. A total number of 290 manuscripts collected were available for the review process. Studies included in a previous systematic review were not duplicated. In total, details of 367 patients were collected, as follows: histological features, clinical presentation, treatment, recurrent rate, treatment of recurrence and outcome...
November 13, 2023: Tumori
#30
LETTER
Francesca Valent, Giulia Degani, Monica Gri, Raffaela Donato, Giulia Varadi, Giovanni Gerardo Cardellino, Gianpiero Fasola
No abstract text is available yet for this article.
October 30, 2023: Tumori
#31
JOURNAL ARTICLE
Andrea Olsen, Alexandra Lebedeva, Polina Nosova, Vladislav Nikulin, Margarita Sharova, Ekaterina Ignatova, Vladislav Mileyko, Maxim Ivanov
INTRODUCTION: Immune checkpoint inhibitors are highly effective in treating various cancers. We analyzed the significance of the KRAS/STK11 co-mutation in relation to the efficacy of immune checkpoint inhibitors in pan-cancer patient cohort. METHODS: We analyzed data from open-access research: MSK-IMPACT (molecular profiling data from patients receiving systemic antitumor therapy) and MSK-TMB (molecular profiling data from patients receiving immune checkpoint inhibitors)...
October 11, 2023: Tumori
#32
REVIEW
Andrea Luciani, Antonio Ghidini, Karen Borgonovo, Maria Chiara Parati, Fausto Petrelli
Patients whose tumours harbour epidermal growth factor receptor (EGFR), and anaplastic lymphoma kinase (ALK) driver mutations can benefit most from treatment with tyrosine kinase inhibitors (TKIs). Most trials with immune checkpoint inhibitors (ICIs) included few patients whose tumour had oncogenic driver alterations. We therefore performed a meta-analysis of studies reporting the activity of ICIs in oncogene addicted NSCLC. A comprehensive search of MEDLINE, The Cochrane Library and EMBASE was conducted to identify relevant studies published up to 31 January 2021...
October 2023: Tumori
#33
REVIEW
Ugo Testa, Germana Castelli, Elvira Pelosi
Anaplastic Lymphoma Kinase (ALK) is a potent oncogenic driver of lung adenocarcinoma (LUAD). ALK is constitutively activated by gene fusion events between the ALK and other gene fusion partners in about 2-3% of LUADs, characterized by few other gene alterations. ALK -fusions are a druggable target through potent pharmacological inhibitors of tyrosine kinase activity. Thus, several ALK-TKIs (Tyrosine Kinase Inhibitors) of first-, second- and third-generation have been developed that improved the outcomes of ALK -rearranged LUADs when used as first- or second-line agents...
September 29, 2023: Tumori
#34
JOURNAL ARTICLE
Bruna Cerbelli, Alessio Cirillo, Giulia Pomati, Angelina Pernazza, Andrea Ascione, Simona Pisegna, Annalinda Pisano, Martina Leopizzi, Maria Gemma Pignataro, Leopoldo Costarelli, Antonino Mulè, Andrea Vecchione, Piera Catalano, Luigi Coppola, Giuseppe Perrone, Letizia Perracchio, Lucia Anemona, Antonio Mastracchio, Stefano Nardi, Renato Reitano, Annalisa Massari, Lucia Rosalba Grillo, Fabrizio Liberati, Carlo Della Rocca, Paolo Marchetti, Andrea Botticelli, Giulia D'Amati
BACKGROUND: Immunotherapy has revolutionized the approach to metastatic triple-negative breast cancers. Atezolizumab was approved for patients with metastatic triple-negative breast cancers whose tumors express PD-L1, determined by SP 142 assay. To assess the availability and practice of SP142 test we administered a survey to all the 15 pathology departments of the Lazio Region during a six-month period. METHODS: The survey comprised 12 questions regarding the availability of SP142 in the pathology departments, the percentage of positive tests, the difficulties of pathologists in cases close to cut-off value and the tested samples...
September 19, 2023: Tumori
#35
JOURNAL ARTICLE
Maria Cristina Leonardi, Matteo Pepa, Mattia Zaffaroni, Maria Giulia Vincini, Rosa Luraschi, Sabrina Vigorito, Anna Morra, Samantha Dicuonzo, Giovanni Carlo Mazzola, Marianna Alessandra Gerardi, Maria Alessia Zerella, Domenico Cante, Edoardo Petrucci, Giuseppina Borzì, Maristella Marrocco, Matteo Chieregato, Luciano Iadanza, Francesca Lobefalo, Marco Valenti, Anna Cavallo, Serenella Russo, Marika Guernieri, Tiziana Malatesta, Ilaria Meaglia, Marco Liotta, Isabella Palumbo, Marta Marcantonini, Emilio Mezzenga, Sara Falivene, Cecilia Arrichiello, Maria Paola Barbero, Giovanni Battista Ivaldi, Gianpiero Catalano, Cristiana Vidali, Caterina Giannitto, Antonella Ciabattoni, Icro Meattini, Cynthia Aristei, Roberto Orecchia, Federica Cattani, Barbara Alicja Jereczek-Fossa
This study quantified the incidental dose to the first axillary level (L1) in locoregional treatment plan for breast cancer. Eighteen radiotherapy centres contoured L1-L4 on three different patients (P1,2,3), created the L2-L4 planning target volume (single centre planning target volume, SC-PTV) and elaborated a locoregional treatment plan. The L2-L4 gold standard clinical target volume (CTV) along with the gold standard L1 contour (GS-L1) were created by an expert consensus. The SC-PTV was then replaced by the GS-PTV and the incidental dose to GS-L1 was measured...
September 9, 2023: Tumori
#36
EDITORIAL
Dario Trapani, Fabio Girardi, Saverio Cinieri, Giuseppe Curigliano
Improved strategies of cancer prevention and control have resulted in tangible benefits for patients with cancer. Disparities in outcome have been reported as a result of inequal access to health care. Historically, differences in health outcomes at population level have been reported according to key characteristics, including race, ethnicity and, more recently, ancestry. These population descriptors have been used to display the differences in the outcome and highlight actionable areas of health disparities, through policy and population health interventions...
September 9, 2023: Tumori
#37
JOURNAL ARTICLE
Laura Sala, Chiara Maura Ciniselli, Fabio Bozzi, Valeria Summo, Chiara Bonini, Silvia Brich, Alessia Bertolotti, Trupia Desiré Viola, Chiara Costanza Volpi, Sara Pizzamiglio, Biagio Paolini, Antonella Aiello, Giovanni Apolone, Paolo Verderio, Umberto Cortinovis
INTRODUCTION: The synthesis of the periprosthetic capsule during implant-based breast reconstruction is the result of a coordinate cascade of inflammatory events ending in a fibrous tissue deposition around the expander or implant. Although the development of small volumes of fluid is one of the complications of prosthetic-based breast reconstruction, the characterization of the periprosthetic effusions coupled with the micro-textured devices, that have been recently introduced after the recall of macro-textured ones, is still lacking...
August 14, 2023: Tumori
#38
JOURNAL ARTICLE
Angioletta Lasagna, Antonella Brunello, Nicola Silvestris, Paolo Pedrazzoli, Massimo Di Maio, Saverio Cinieri
BACKGROUND: Patients with cancer present a higher risk of vaccine-preventable diseases. Recommended vaccinations are the most cost-effective measure to reduce the risk of transmission and related complications. Nevertheless, vaccination rates are inadequate. Oncologists have a central role in tailored vaccine communication to their patients. We present the results of a survey conducted by AIOM in 2022, focusing on the perception of the problem by oncologists. MATERIALS AND METHODS: An anonymous 31-item online questionnaire was shared on 15 September 2022 on the AIOM website...
August 10, 2023: Tumori
#39
EDITORIAL
Celeste Cagnazzo, Bruno Ficara, Federica Palermo, Franca Fagioli
The consequences of the Italian privacy legislation, that represents a very restrictive implementation of the general European regulation on data protection, have mainly been felt at the level of observational research. In this field is not always possible to obtain the consent of subjects, and as for retrospective studies, it is not currently clear which is the correct regulatory procedure to follow. This uncertainty in the law's implementation has given way to multiple interpretations, making it difficult to obtain a homogeneous path in Italy...
August 7, 2023: Tumori
#40
JOURNAL ARTICLE
Kamala Dhakal, Panpan Wang, Joanes Faustine Mboineki, Mikiyas Amare Getu, Changying Chen, Daya Laxmi Shrestha
INTRODUCTION: Patients with cervical cancer report experiencing physical, psychological, economic, and social problems daily. An exploration of supportive care needs is important for patients and their families to cope with diagnosis, treatment, recovery or even death. OBJECTIVE: This study explores the perceived supportive care needs of Nepali patients with cervical cancer who are undergoing cancer treatment. METHODS: A descriptive qualitative research design was utilized with semi-structured interviews to probe patients with cervical cancer's supportive care needs...
August 2023: Tumori
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
